X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2935) 2935
Book Review (1003) 1003
Publication (254) 254
Book Chapter (17) 17
Conference Proceeding (14) 14
Trade Publication Article (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2284) 2284
humans (2198) 2198
rituximab (1850) 1850
anti-cd20 monoclonal-antibody (1776) 1776
oncology (911) 911
female (877) 877
antibodies, monoclonal - therapeutic use (871) 871
antibodies, monoclonal, murine-derived (859) 859
male (835) 835
non-hodgkins-lymphoma (813) 813
hematology (755) 755
middle aged (717) 717
therapy (676) 676
adult (663) 663
aged (566) 566
treatment outcome (552) 552
chronic lymphocytic-leukemia (478) 478
antineoplastic agents - therapeutic use (458) 458
b-cell lymphoma (455) 455
animals (449) 449
immunology (420) 420
anti-cd20 (407) 407
follicular lymphoma (396) 396
anti-cd20 antibody (362) 362
antibodies, monoclonal - administration & dosage (339) 339
lymphoma (338) 338
chemotherapy (323) 323
immunotherapy (316) 316
antineoplastic combined chemotherapy protocols - therapeutic use (313) 313
cancer (310) 310
antigens, cd20 - immunology (301) 301
lymphomas (272) 272
monoclonal antibodies (268) 268
care and treatment (260) 260
transplantation (252) 252
abridged index medicus (248) 248
b-lymphocytes - immunology (246) 246
mice (237) 237
antibodies, monoclonal - adverse effects (230) 230
cd20 (230) 230
radioimmunotherapy (227) 227
low-grade (224) 224
pharmacology & pharmacy (223) 223
antibodies, monoclonal, murine-derived - therapeutic use (220) 220
efficacy (220) 220
aged, 80 and over (213) 213
immunologic factors - therapeutic use (211) 211
in-vivo (204) 204
antibodies, monoclonal - pharmacology (203) 203
lymphoma, b-cell - drug therapy (202) 202
rheumatoid-arthritis (192) 192
phase-ii (189) 189
systemic-lupus-erythematosus (182) 182
b-lymphocytes - drug effects (176) 176
lymphoma, non-hodgkin - drug therapy (175) 175
phase-ii trial (175) 175
drug therapy (172) 172
trial (171) 171
rheumatology (170) 170
clinical trials as topic (162) 162
medicine & public health (161) 161
antineoplastic agents - administration & dosage (159) 159
adolescent (158) 158
health aspects (156) 156
disease-free survival (154) 154
hemic and lymphatic diseases (154) 154
remission induction (152) 152
lymphoma, follicular - drug therapy (149) 149
medicine, research & experimental (149) 149
b-cell depletion (147) 147
research (147) 147
prognosis (145) 145
apoptosis (143) 143
antineoplastic agents - pharmacology (142) 142
recurrence (142) 142
analysis (140) 140
chop chemotherapy (140) 140
non-hodgkin's lymphoma (140) 140
in-vitro (137) 137
leukemia, lymphocytic, chronic, b-cell - drug therapy (137) 137
antibodies, monoclonal - immunology (136) 136
b cells (136) 136
combined modality therapy (133) 133
antibodies (126) 126
disease (126) 126
retrospective studies (126) 126
antineoplastic agents (125) 125
follow-up studies (124) 124
immune system diseases (124) 124
monoclonal-antibody (124) 124
safety (124) 124
immunosuppressive agents - therapeutic use (123) 123
b-cells (121) 121
double-blind (120) 120
non-hodgkin's lymphomas (120) 120
stem-cell transplantation (120) 120
time factors (120) 120
monoclonal antibody (119) 119
antineoplastic agents - adverse effects (117) 117
cell line, tumor (117) 117
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2815) 2815
French (63) 63
German (33) 33
Spanish (20) 20
Korean (5) 5
Russian (5) 5
Japanese (4) 4
Chinese (3) 3
Turkish (3) 3
Czech (2) 2
Polish (2) 2
Portuguese (2) 2
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3716 - 3725
Distinct genes encode 6 human receptors for IgG (hFc gamma Rs), 3 of which have 2 or 3 polymorphic variants. The specificity and affinity of individual hFc... 
DEPENDENT CELLULAR CYTOTOXICITY | WEGENERS-GRANULOMATOSIS | RHEUMATOID-ARTHRITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | NATURAL-KILLER-CELLS | ANTI-CD20 MONOCLONAL-ANTIBODY | HUMAN-NEUTROPHILS | LIGAND-BINDING | ALLELIC POLYMORPHISM | THERAPEUTIC ACTIVITY | HEMATOLOGY
Journal Article
Scandinavian Journal of Gastroenterology, ISSN 0036-5521, 05/2017, Volume 52, Issue 5, pp. 606 - 608
Journal Article
Annales d'Endocrinologie, ISSN 0003-4266, 02/2017, Volume 78, Issue 1, pp. 20 - 26
Objectives Graves’ ophthalmopathy occurs in 50% of Graves’ disease cases. Treatment is based on smoking cessation, and control of the euthyroidism and ocular... 
Anti-CD20 | Optic neuropathy | Graves ophthalmopathy | Rituximab
Journal Article
Pediatric Research, ISSN 0031-3998, 10/2018, Volume 84, Issue 4, pp. 520 - 526
BACKGROUND: Rituximab, a monoclonal antibody targeting B lymphocytes, effectively sustains remission in steroid-dependent nephrotic syndrome (SDNS). We studied... 
RESISTANT | MULTICENTER | ACTIVATION | EFFICACY | SAFETY | ANTI-CD20 ANTIBODY | PEDIATRICS | RECONSTITUTION | EXPRESSION | TH17 CELLS | CHILDREN | Lymphocytes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 12, pp. 1101 - 1110
Journal Article
NEW ENGLAND JOURNAL OF MEDICINE, ISSN 0028-4793, 02/2005, Volume 352, Issue 5, pp. 441 - 449
BACKGROUND: Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy is effective in patients who have had a relapse... 
MEDICINE, GENERAL & INTERNAL | B-CELL LYMPHOMA | ANTI-CD20 MONOCLONAL-ANTIBODY | RITUXIMAB | RADIOIMMUNOTHERAPY | NON-HODGKINS-LYMPHOMA | TERM-FOLLOW-UP | LOW-GRADE | STAGE-I | IODINE I-131 TOSITUMOMAB | CHEMOTHERAPY
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2005, Volume 23, Issue 3, pp. 474 - 481
Purpose Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). Polymorphisms in FcgammaRIIIA (CD16) receptor expression modulate human... 
CELLS | ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | IGG | PHASE-II | FOLLICULAR LYMPHOMA | BINDING
Journal Article
Journal of Neurosurgery, ISSN 0022-3085, 06/2012, Volume 116, Issue 6, pp. 1318 - 1323
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 5, pp. 544 - 551
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment,... 
THERAPY | RESPONSE CRITERIA | ONCOLOGY | CHOP | MONOCLONAL ANTI-CD20 ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | COMBINATION | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | PROGNOSTIC VALUE | TRANSPLANTATION | Index Medicus
Journal Article
Journal Article
European Journal of Immunology, ISSN 0014-2980, 03/2019, Volume 49, Issue 3, pp. 500 - 503
B-ReDi mice express a red fluorescent protein together with the diphtheria toxin receptor selectively in B cells. B cells can be effectively visualized by red... 
B cell receptor | anti-CD20 | DTR | B cells | THERAPY | GENE | B cells | IMMUNOLOGY | B cell receptor | EXPRESSION | LINEAGE
Journal Article
Neurology, ISSN 0028-3878, 04/2018, Volume 90, Issue 20, pp. E1805 - E1814
OBJECTIVETo assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of... 
RHEUMATOID-ARTHRITIS | OCRELIZUMAB | TRIAL | ANTI-CD20 MONOCLONAL-ANTIBODY | IMMUNOTHERAPY | PHASE-I/II | INADEQUATE RESPONSE | RITUXIMAB | DOUBLE-BLIND | HUMAN CD20 | CLINICAL NEUROLOGY | 132 | 120
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 01/2019, Volume 10
A number of different B cell subsets have been shown to exhibit regulatory activity using a variety of mechanisms to attenuate inflammatory diseases. Here we... 
MAINTENANCE | ANTI-CD20 MONOCLONAL-ANTIBODY | THERAPY | MULTIPLE-SCLEROSIS | AUTOIMMUNITY | RITUXIMAB | MULTIDISCIPLINARY SCIENCES | PROLIFERATION | MECHANISMS | SUPPRESSION | IL-10
Journal Article
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 08/2017, Volume 31, Issue 8, pp. e350 - e351
Journal Article